Posted by Michael Wonder on 20 Oct 2021
ICER publishes final evidence report and policy recommendations on therapies for myasthenia gravis
20 October 2021 - Independent appraisal committee found the evidence is adequate to demonstrate that eculizumab and efgartigimod both provide a net health benefit when compared to conventional therapy alone.
The Institute for Clinical and Economic Review today released a Final Evidence Report assessing the comparative clinical effectiveness and value of eculizumab (Soliris; Alexion Pharmaceuticals) and efgartigimod (argenx, Halozyme Therapeutics and Zai Lab) for the treatment of generalized myasthenia gravis.
